Catalent Pharma Solutions is to invest $2.5 million in a new, second clinical supply facility in Shanghai, China, due to open in early 2019. When completed, the facility is expected to employ 100 people and will double Catalent’s total clinical storage capacity in China.
The new 30,000 square-feet facility in Tangzhen, a district of Shanghai, will have three controlled temperature rooms operating at 2-8°C, 15-25°C, and -20°C, and will also offer returns and destruction services. The company says that the location for the new facility, outside of the Free Trade Zone (FTZ), will provide clinical trial sponsors with increased speed and efficiency when running trials in China, and that its proximity to Catalent’s existing FTZ facility in Waigaoqiao, within China’s Zhangjiang Pharma Valley, will allow it to offer sponsors an optimised clinical supply solution for studies in both China and beyond.
Catalent will offer its FastChain demand-led supply services from the new facility, as well as from the existing FTZ site, affording sponsors access to in-country GMP secondary packaging, final assembly, labelling and distribution of clinical supplies inside China, and in the wider Asia-Pacific region. These supply services are designed to reduce the time it takes for clinical sites to receive patient kits and to reduce waste from clinical trial material.
The existing Waigaoqiao facility, opened in 2013, provides FTZ access, primary packaging, FastChain supply services, secondary packaging, clinical storage and global distribution services.
For further information about Catalent Pharma Services visit www.catalent.com
- Leading cell culture media company changes name to FUJIFILM Irvine Scientific, Inc
- Sangamo finalises TxCell acquisition
- Battery Ventures acquires TTP Labtech
- Avacta agrees Affimer reagent licensing deal with New England Biolabs
- TxCell terminates OCABSA financing programme following majority stake acquisition by Sangamo
- Aigenpulse expands into new facilities in Oxford, UK and Boston, USA
- Metrion Biosciences and AMRI collaborate on ion channel drug discovery services
- Avacta Group and Tufts University School of Medicine collaborate to develop novel class of drug conjugate
- Endomag raises $10 million to establish new standard of breast cancer care
- Isogenica licenses CIS Display Technology to Aro Biotherapeutics for Centyrin-based biopharmaceutical development
Latest from Tom Mulligan
- SGS’s first malaria human challenge trial will take place in Belgium this month
- TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products
- Horizon Discovery extends CRISPR Screening Service to primary human T cells
- TrakCel and The Quick Life Science Group partner on supply chain IT solution for cell and gene therapies
- Almac Group extends personalised cancer vaccine production facilities
- Cobra Biologics appoints Dr Darrell Sleep as Director of Innovation
- Phico Therapeutics appoints financial director and two non-executive directors
- Evonetix appoints Stephanie Brooking as Head of Product Management
- Bio-Rad publishes new findings on generation and characterisation of drug-target-complex-specific antibodies
- Expedeon licenses Lightning-Link rapid biotinylation technology to Cell Guidance Systems